高分子风险早期乳腺癌的部分乳腺照射
本研究比较Oncotype DX复发评分(ODX RS)>25的高分子风险早期乳腺癌患者接受部分乳腺照射(PBI)与全乳照射(WBI)的肿瘤学结局。倾向评分匹配后PBI组28例、WBI组140例,72个月局部复发累积发生率分别为7.9%与4.8%(P=.6),差异无统计学意义。
要点
- ODX RS>25患者中PBI与WBI的72个月局部复发累积发生率无显著差异。
- PBI组3例局部复发中2例位于原发灶不同象限。
- 结论需更大样本和更长随访验证PBI在此类患者中的安全性。
核心结论
- 在高ODX RS(>25)患者队列中局部复发事件较少,PBI与WBI之间未发现统计学显著的局部复发差异。
- 这些发现提示经仔细选择的高基因组风险患者可考虑PBI,但需更大规模、更长随访研究来确定其安全性。
研究设计与样本
- 回顾性队列研究,患者来自前瞻性维护的机构数据库。
- 纳入968例ODX RS>25并接受辅助放疗的患者,中位年龄59岁(范围25-86),中位随访5.3年。
- 采用倾向评分匹配按1:5生成可比PBI与WBI队列,匹配后PBI组28例、WBI组140例。
- 主要评估局部复发(LR)发生率与放疗方式的关系。
主要发现
- 匹配队列中PBI组观察到3例局部复发事件,其中2例位于原发灶不同象限。
- 匹配队列中WBI组观察到5例局部复发事件。
- ODX RS>25队列中PBI后72个月局部复发累积发生率为7.9%(95%CI,1.3%-23%)。
- WBI后72个月局部复发累积发生率为4.8%(95%CI,1.6%-11%),P=.6。
关键数值与推荐
- 高危分子风险定义为Oncotype DX复发评分(ODX RS)>25。
- 匹配后PBI组28例与WBI组140例进行比较。
- 局部复发累积发生率评估时间点为72个月。
临床怎么用
- 对于ODX RS>25的早期乳腺癌患者,PBI与WBI的局部复发差异未达统计学显著,提示PBI可考虑用于经仔细选择的高基因组风险患者。
- 由于事件数少且随访有限,不能据此常规推广PBI用于所有高ODX RS患者,需个体化决策并告知证据局限性。
局限性
- PBI组样本量小(匹配后28例),局部复发事件数少。
- 中位随访5.3年,缺乏更长随访数据。
- 分子/基因组特征用于放疗决策仍属研究性,结论需更大规模研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Partial breast irradiation (PBI) is a suitable and well-tolerated alternative to whole breast irradiation (WBI) following lumpectomy for many forms of low-risk, early-stage breast cancer. Molecular risk scores, such as the Oncotype DX recurrence score (ODX RS), are increasingly guiding systemic treatment decisions. However, molecular/genomic profiling for radiation therapy (RT) decision-making remains investigational, and it is unclear whether a high ODX RS should preclude the use of PBI. We compared oncologic outcomes among patients with high ODX RS (>25) treated with PBI versus WBI. METHODS AND MATERIALS: Patients who underwent breast conservation followed by PBI or WBI with ODX RS > 25 were ascertained from a prospectively maintained institutional database. Comparable PBI and WBI cohorts were generated in 1:5 fashion using propensity score matching based on salient clinicopathologic features. We evaluated the incidence of local recurrence (LR) as a function of RT approach. RESULTS: We identified 968 patients with an ODX RS > 25 who were treated with adjuvant RT, with a median age of 59 years (range, 25-86) and a median 5.3 years of follow-up. In a propensity matched cohort analysis that included 28 patients who received PBI matched to 140 who received WBI, we observed 3 LR events among those receiving PBI (2 of which were in different quadrants from the primary lesion) and 5 events among those receiving WBI. Among this cohort with ODX RS > 25, the 72-month cumulative incidence of LR following PBI was 7.9% (95% CI, 1.3%-23%) compared to 4.8% (95% CI, 1.6%-11%) following WBI (P = .6). CONCLUSIONS: In this cohort of patients with high ODX RS, few LRs were observed, and no statistically significant difference in LR was identified between PBI and WBI. Although these findings suggest that PBI may be considered in carefully-selected high-genomic-risk patients, larger studies with longer follow-up are needed to definitively establish the safety of this approach.
引用
- Terry AR, Boe L, Pawloski KR, et al. Partial Breast Irradiation for High Molecular Risk Early-Stage Breast Cancer. Int J Radiat Oncol Biol Phys. 2025. PMID: 41026069. doi:10.1016/j.ijrobp.2025.04.044
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。